title: Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned?
abstract: Congestive heart failure (CHF) is a primary cause of morbidity and mortality with an increasing prevalence in human and canine populations. Recognition of the role of renin-angiotensin-aldosterone system (RAAS) overactivation in the pathophysiology of CHF has led to significant medical advances. By decreasing systemic vascular resistance and angiotensin II (AII) production, angiotensin-converting enzyme (ACE) inhibitors such as benazepril improve cardiac hemodynamics and reduce mortality in human and dog CHF patients. Although several experiments have pointed out that efficacy of ACE inhibitors depends on the time of administration, little attention is paid to the optimum time of dosing of these medications. A thorough characterization of the chronobiology of the renin cascade has the potential to streamline the therapeutic management of RAAS-related diseases and to help determining the optimal time of drug administration that maximizes efficacy of ACE inhibitors, while minimizing the occurrence of adverse effects. We have developed an integrated pharmacokinetic-pharmacodynamic model that adequately captures the disposition kinetics of the paradigm drug benazeprilat, as well as the time-varying changes of systemic renin-angiotensin-aldosterone biomarkers, without and with ACE inhibition therapy. Based on these chronobiological investigations, the optimal efficacy of ACE inhibitors is expected with bedtime dosing. The data further show that benazepril influences the dynamics of the renin-angiotensin-aldosterone cascade, resulting in a profound decrease in AII and aldosterone (ALD), while increasing renin activity for about 24 h. From the results of recent investigations in human, it is hypothesized that reduction of AII and ALD is one of the drivers of increased survival and improved quality of life in dogs receiving ACE inhibitors. To support and consolidate this hypothesis, additional efforts should be directed toward the collection of circulating RAAS peptides in spontaneous cases of canine CHF. If such a link could be established, profiling of these biomarkers could support determination of the severity of heart failure, complement clinical and echocardiographic findings, and be used for therapeutic drug monitoring purposes.
authors.affiliation: Department of Pharmacology, Leiden-Academic Centre for Drug Research, 2300, Leiden, The Netherlands. jonathan.mochel@hotmail.com.|Department of Integrated Quantitative Sciences, Novartis Campus, St. Johann, 4002, Basel, Switzerland. jonathan.mochel@hotmail.com.
authors.forename: Jonathan P
authors.initials: JP
authors.lastname: Mochel
authors.affiliation: Department of Pharmacology, Leiden-Academic Centre for Drug Research, 2300, Leiden, The Netherlands.
authors.forename: Meindert
authors.initials: M
authors.lastname: Danhof
mesh_terms: D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D002940:Circadian Rhythm; D004285:Dogs; D004573:Electrolytes / Q000652:urine; D006333:Heart Failure / Q000188:drug therapy; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology; D066253:Vascular Remodeling
chemical_list: D001552:Benzazepines; D004573:Electrolytes; C044946:benazepril
keywords: Chronobiology; Heart failure; PKPD modeling; RAAS